Edition:
India

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

1.47USD
1:30am IST
Change (% chg)

$0.01 (+0.68%)
Prev Close
$1.46
Open
$1.46
Day's High
$1.48
Day's Low
$1.45
Volume
2,570
Avg. Vol
38,759
52-wk High
$6.15
52-wk Low
$1.29

Chart for

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)

Overall

Beta: 3.74
Market Cap(Mil.): $22.80
Shares Outstanding(Mil.): 11.40
Dividend: --
Yield (%): --

Financials

BRIEF-Cyclacel Pharmaceuticals Posts Qtrly Loss Of $2.1 Mln

* CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

29 Mar 2018

BRIEF-Cyclacel Pharma Projects Cash Resources To Fund Currently Planned Programs Through End Of 2019

* CYCLACEL PHARMACEUTICALS INC - CO PROJECTS CASH RESOURCES TO FUND CURRENTLY PLANNED PROGRAMS THROUGH END OF 2019 Source text for Eikon: Further company coverage:

09 Jan 2018

BRIEF-Cyclacel Pharmaceuticals Q3 loss per share $0.91 including items

* Cyclacel Pharmaceuticals reports third quarter 2017 financial results

10 Nov 2017

BRIEF-Intra-Cellular Therapies Q3 loss per share $0.53

* Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update

08 Nov 2017

Competitors

Earnings vs. Estimates